Skip to main content
. 2021 Mar 25;9(3):e001504. doi: 10.1136/jitc-2020-001504

Figure 5.

Figure 5

(A) Overall response rate to pembrolizumab±chemotherapy in patients with decrease versus increase in plasma ctDNA at the first follow-up. (B) Progression-free survival (PFS) and (C) overall survival (OS) to pembrolizumab±chemotherapy in patients with decrease versus increase in plasma ctDNA at the first follow-up blood sampling. ctDNA, circulating tumor DNA.